Related Experiment Videos
Hemophagocytic syndrome
A H Al-Talag1, A E Mohamed, M M Dafulla
1Department of Gastroenterology, Riyadh Armed Forces Hospital, Riyadh, Kingdom of Saudi Arabia.
Saudi Medical Journal
|May 23, 2001
Summary
This case report details a patient with Epstein-Barr virus-associated hemophagocytic syndrome. Intravenous Ganciclovir demonstrated significant efficacy in treating this rare condition, offering a potential therapeutic avenue.
Area of Science:
- Hematology
- Virology
- Immunology
Background:
- Virus-associated hemophagocytic syndrome (VAHS) is a rare, life-threatening condition characterized by excessive immune activation.
- Epstein-Barr virus (EBV) is a common viral trigger for VAHS, particularly in immunocompetent individuals.
Observation:
- An elderly male presented with prolonged fever, weight loss, hepatosplenomegaly, jaundice, pancytopenia, and elevated liver enzymes.
- Diagnostic workup revealed a positive Monospot test and EBV-specific IgG, alongside characteristic findings of hemophagocytosis in liver and bone marrow biopsies.
Findings:
- The patient's symptoms were refractory to antibiotics, anti-tuberculosis therapy, and partially responsive to steroids.
- Intravenous Ganciclovir led to a complete resolution of symptoms, normalization of laboratory parameters, and weight restoration.
- Relapse occurred upon Ganciclovir cessation, with limited response to oral antivirals and other immunosuppressive therapies, highlighting the critical role of sustained Ganciclovir treatment.
Implications:
- This case underscores EBV as a likely cause of VAHS in this patient, confirmed by splenic biopsy.
- Sustained Ganciclovir therapy is crucial for viral eradication and effective management of EBV-associated hemophagocytic syndrome.
- The findings suggest Ganciclovir as a valuable therapeutic option for virus-associated hemophagocytic syndrome, emphasizing the need for prolonged treatment protocols.